Core Viewpoint - The company has presented preliminary data for IBI363 at the ASCO conference, demonstrating breakthrough efficacy in both hot tumors (NSCLC) and cold tumors (MSS CRC/mucosal melanoma) [1][2]. Group 1: Efficacy Data - In NSCLC, patients treated with IBI363 at a dose of 3 mg/kg showed a median progression-free survival (mPFS) of 7.3 months, indicating excellent performance [1][2]. - For MSS CRC, the median overall survival (mOS) reached 16.1 months in a mixed-dose single-agent treatment, approaching the benefits seen in first-line patients [1][3]. - In squamous NSCLC, the clinical objective response rate (cORR) was 36.7% with a disease control rate (DCR) of 90.0% [2]. - In cold tumors, IBI363 demonstrated an mOS of 16.1 months in MSS CRC, significantly exceeding the current treatment standard of 9-10 months [3][4]. Group 2: Safety Profile - The incidence of treatment-emergent adverse events (TEAEs) was reported at 99.3%, with 42.6% being grade 3 or higher [2]. - Only 6.6% of patients discontinued treatment due to TEAEs, and the mortality rate attributed to TEAEs was very low at 2.9% [2]. Group 3: Future Developments - The company plans to communicate with regulatory authorities regarding key registration clinical trials for squamous NSCLC, with expectations to initiate Phase III trials within the year [3][6]. - IBI363 is anticipated to reshape the immune environment for IO-resistant lung cancer patients, potentially replacing docetaxel as the new standard of care [2][4]. Group 4: Pipeline and Financial Outlook - The company is advancing its core pipeline, with expectations for multiple catalysts in 2025, including new indications for existing products [5][6]. - Revenue projections for the company are estimated at 11.856 billion, 15.613 billion, and 21.479 billion yuan for 2025-2027, with a target market valuation of 131.9 billion HKD [6].

Company Updates - On May 23, 2025 ASCO conference, several significant data were released by Innovent Biologics, including multiple oral presentations, notably the PoC data for IBI363 (PD-1/IL-2) in melanoma, colorectal cancer, and non-small cell lung cancer [1] - IBI363's colorectal cancer data exceeded expectations, with an overall objective response rate (ORR) of 12.7% for monotherapy and 23.5% for combination therapy, and a median overall survival (mOS) of 16.1 months for monotherapy [1] - In the context of IO-treated lung cancer, IBI363 demonstrated strong competitive advantages, with an ORR of 43.3% in the squamous NSCLC group at a 3 mg/kg dose [1] Key Data from ASCO - IBI363 showed an ORR of 26% and a median progression-free survival (mPFS) of 5.7 months in IO-treated mucosal/limb melanoma [2] - IBI343 (CLDN18.2 ADC) reported an ORR of 22.7%, mPFS of 5.4 months, and mOS of 8.5 months in CLDN18.2+ pancreatic ductal adenocarcinoma (PDAC), with 2L patients showing an mOS of 12.1 months [2] Profit Forecast and Valuation - The company maintains its net profit forecasts for 2025 and 2026 at 472 million and 1.298 billion respectively, and has raised the target price by 4.5% to HKD 69, indicating a potential upside of 22.7% from the current stock price [2]

Group 1 - The Hong Kong stock market shows resilience with the Hang Seng Index rising by 1.1% and a net inflow of southbound funds amounting to HKD 18.959 billion this week, bringing the total net inflow for the year to over HKD 622.9 billion, a 1.5 times increase compared to the same period last year [1][3] - Dividend sectors, particularly banks, are favored by investors, with China Construction Bank attracting nearly HKD 6 billion in net inflows this week [1][2] - The AH share premium index has dropped to a near four-year low, with the premium of A-shares over H-shares narrowing to 31%, down from a high of 61% in 2024 [3] Group 2 - Southbound funds have shown a preference for the banking sector, with net inflows of HKD 7.196 billion, while the pharmaceutical and telecommunications sectors received net inflows of HKD 4.859 billion and HKD 3.287 billion, respectively [1][2] - Major stocks such as China Construction Bank, Meituan-W, and China Mobile saw significant net inflows, while Tencent Holdings and Alibaba-W experienced net outflows [2] - The overall sentiment in the Hong Kong market is improving, with institutions optimistic about the long-term value of Hong Kong stocks, suggesting a focus on dividend stocks as a stable investment during uncertain times [4] Group 3 - The liquidity of Hong Kong stocks has improved significantly due to the inflow of southbound and overseas funds, with the proportion of Hong Kong Stock Connect holdings increasing from 8% in September 2020 to 20% [3] - The internationalization of the Hong Kong stock market is accelerating, with significant foreign investment interest, as evidenced by the participation of non-U.S. foreign investors in major listings [4] - Analysts suggest that as the U.S. economy weakens and the dollar enters a downtrend, Hong Kong stocks are positioned to benefit from the resulting liquidity influx [4]

5月23日恒生指数上涨0.24%，南向资金全天合计成交金额为963.65亿港元，其中，买入成交476.13亿港 元，卖出成交487.52亿港元，合计净卖出金额11.39亿港元。具体来看，港股通（深）累计成交金额 352.18亿港元，买入成交161.92亿港元，卖出成交190.25亿港元，合计净卖出金额28.33亿港元；港股通 （沪）累计成交金额611.47亿港元，买入成交314.21亿港元，卖出成交297.27亿港元，合计净买入金额 16.94亿港元。 成交活跃股方面，今日上榜个股中，南向资金成交金额最多的是小米集团-W，合计成交额58.61亿港 元，腾讯控股、阿里巴巴-W成交额紧随其后，分别成交41.27亿港元、38.56亿港元。以净买卖金额统 计，净买入的个股共有8只，美团-W净买入额为8.42亿港元，净买入金额居首，该股收盘股价上涨 0.66%，建设银行净买入额为6.23亿港元，信达生物净买入额为4.12亿港元。净卖出金额最多的是盈富 基金，净卖出23.24亿港元，该股收盘股价上涨0.25%，腾讯控股、小米集团-W遭净卖出15.65亿港元、 6.53亿港元。 今日上榜个股中，美团-W、信达生物、阿里巴巴 ...

Core Viewpoint - The Hong Kong stock market experienced a net sell-off of 11.39 billion HKD from northbound trading, with significant variations between Shanghai and Shenzhen stock connect transactions [1] Group 1: Northbound Trading Activity - Northbound trading saw a net buy of 16.94 billion HKD through Shanghai Stock Connect and a net sell of 28.33 billion HKD through Shenzhen Stock Connect [1] - The most bought stocks included Meituan-W (03690), China Construction Bank (00939), and Innovent Biologics (01801) [1] - The most sold stocks included the Tracker Fund of Hong Kong (02800), Tencent (00700), and Xiaomi Group-W (01810) [1] Group 2: Stock-Specific Insights - Meituan-W (03690) received a net buy of 8.42 billion HKD, with expectations of a 30.6% year-on-year increase in adjusted net profit for Q1 2025 [4] - China Construction Bank (00939) and Bank of China (03988) saw net buys of 6.22 billion HKD and 1.97 billion HKD, respectively, following a reduction in deposit rates [5] - Innovent Biologics (01801) had a net buy of 4.11 billion HKD, with promising data from the 2025 ASCO conference [5] - Xpeng Motors-W (09868) received a net buy of 2.88 billion HKD, with expectations of improved profit margins in Q2 [6] - Xiaomi Group-W (01810) faced a net sell of 6.53 billion HKD amid product announcements and market speculation [6] - Tencent (00700) experienced a net sell of 15.64 billion HKD, despite stable Q1 performance and long-term growth strategies in AI [7] - The Tracker Fund of Hong Kong (02800) saw a significant net sell of 23.24 billion HKD, attributed to a lack of market catalysts [7]

Core Insights - The National Medical Products Administration (NMPA) has proposed to include Innovent Biologics' IBI363, a PD-1/IL-2 bispecific antibody fusion protein, in its breakthrough therapy designation for treating locally advanced or metastatic squamous non-small cell lung cancer that has failed platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy [1][2] Group 1: Product Development - IBI363 is a globally innovative PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics, designed to block the PD-1/PD-L1 pathway while activating the IL-2 pathway [1] - The IL-2 arm of IBI363 has been engineered to retain affinity for IL-2 Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby lowering toxicity [1] - IBI363 has demonstrated good anti-tumor activity in various tumor-bearing pharmacology models and has shown significant tumor suppression efficacy in PD-1 resistant and metastatic models [1] Group 2: Clinical Research and Regulatory Status - IBI363 has previously been included in the breakthrough therapy drug (BTD) list by CDE, targeting unresectable locally advanced or metastatic acral and mucosal melanoma that has not undergone systemic treatment [2] - Innovent Biologics is conducting clinical studies in China, the United States, and Australia to explore the efficacy and safety of IBI363 against various malignancies [2] - IBI363 has received two Fast Track designations from the U.S. FDA for the treatment of advanced squamous non-small cell lung cancer and melanoma [2]

Group 1 - The pharmaceutical sector in Hong Kong is experiencing a strong rally, with notable gains in stocks such as Kailaiying, which rose over 14%, and Sangfor Pharmaceuticals, which increased by 7.6% [1][2] - Sangfor Pharmaceuticals announced a licensing agreement with Pfizer, receiving an upfront payment of $1.25 billion, which significantly boosted investor confidence [1] - The China National Medical Products Administration has accepted a new drug application for cyclosporine eye gel from Zhaoke Ophthalmology, indicating positive regulatory developments in the industry [1] Group 2 - Longcheng Securities expressed optimism about the pharmaceutical sector, citing frequent favorable policies that are expected to lead to a steady recovery in industry sentiment [1] - Morgan Stanley's research report maintains a positive outlook on the Chinese pharmaceutical industry, highlighting supportive policies for innovation and low dependency on U.S. exports, which mitigates risks from geopolitical tensions and uncertainties in U.S. drug pricing [1]

Core Insights - The Hong Kong stock market saw a net inflow of 63.32 billion HKD from northbound trading on May 20, with 43.05 billion HKD from the Shanghai Stock Connect and 20.27 billion HKD from the Shenzhen Stock Connect [1][2] Group 1: Net Inflows and Outflows - The most bought stocks included Meituan-W (03690), China Mobile (00941), and China Construction Bank (00939) [1][2] - The most sold stocks included Xiaomi Group-W (01810), Tencent (00700), and Sanofi (01530) [1][2] Group 2: Individual Stock Performance - Meituan-W (03690) received a net inflow of 12.33 billion HKD, with plans to launch an AI programming tool called "NoCode" aimed at non-technical users [5] - China Mobile (00941) saw a net inflow of 5.5 billion HKD, supported by government initiatives to accelerate 5G-A and 6G technology development [5] - China Construction Bank (00939) had a net inflow of 4.99 billion HKD, following a reduction in deposit rates by major banks [6] - Sanofi (01530) experienced a net outflow of 1.2 billion HKD after a significant stock price increase due to a licensing deal with Pfizer [7] - Other notable net inflows included Kangfang Biopharma (09926) with 4.85 billion HKD and Semiconductor Manufacturing International Corporation (00981) with 2.01 billion HKD [7]

截至2025年5月20日 09:35，恒生医疗保健指数(HSHCI)强势上涨2.69%，成分股三生制药(01530)上涨33.93%，欧康维视生物-B(01477)上涨7.44%，再鼎医药 (09688)上涨6.39%，石药集团(01093)，诺诚健华(09969)等个股跟涨。恒生医疗ETF(513060)高开高走上涨2.48%，冲击3连涨。最新价报0.50元。流动性方 面，恒生医疗ETF盘中换手2.6%，成交2.66亿元。拉长时间看，截至5月19日，恒生医疗ETF近1月日均成交12.37亿元，居可比基金第一。 湘财证券指出，近期在国家鼓励创新大背景下创新药产业链表现活跃，虽然医药工业复苏仍有待验证，行业受医保控费压力仍在，但多层次的支付体系正在 建立，医疗需求的刚性将共同推动行业企稳回升，建议关注高成长及预期改善两大方向，具体而言：（1）高成长：医药外包服务中的ADCCDMO、减肥药 产业链多肽CDMO等方向公司。（2）预期改善：盈利能力有望触底回升的第三方检验医学实验室，消费医疗中的眼科及口腔等方向的公司。 恒生医疗ETF紧密跟踪恒生医疗保健指数，恒生医疗保健指数提供一项市场参考指标，反映在香港上市、主要 ...

Core Viewpoint - The article discusses the completion of the first patient dosing in a Phase III clinical trial (GLORY-3) for the dual receptor agonist, Masitide, in overweight or obese patients with Metabolic Associated Fatty Liver Disease (MAFLD) in China [1][2]. Group 1: Clinical Study Overview - The GLORY-3 study is a multicenter, randomized, open-label Phase III trial comparing the efficacy and safety of Masitide (9 mg) with Semaglutide (2.4 mg) in approximately 470 overweight or obese participants (BMI ≥ 27 kg/m²) with MAFLD [2]. - The primary endpoints include the percentage change in liver fat content assessed by MRI-PDFF from baseline at 48 weeks and the percentage change in body weight from baseline at 48 weeks [2]. Group 2: Efficacy Results - In a Phase II study involving obese participants (BMI ≥ 30 kg/m²), the Masitide 9 mg group showed a weight reduction of -18.6% compared to the placebo group, with an average weight change of -17.8 kg [3]. - Among participants with a baseline liver fat content exceeding 5%, the Masitide 9 mg group demonstrated a 73.3% average percentage decrease in liver fat content after 24 weeks, which was maintained at 48 weeks [3]. Group 3: Clinical Significance - MAFLD is the most common chronic liver disease globally and has replaced viral hepatitis as the leading chronic liver disease in China, with an MAFLD prevalence of 81.8% among the obese population [4]. - GLP-1 receptor agonists like Semaglutide are recommended for the treatment of obesity with MAFLD, and Masitide, as a dual receptor agonist, is expected to provide significant benefits in reducing liver fat and enzyme levels [4][5].